Evaluation of Transdermal Nicotine Replacement Therapy (NRT) Activity Through Metabolic Induction

Smoking Clinical Trial

Official title:

Evaluation of Nicotine Receptor Up-regulation Activity Through Metabolic Induction and Changes in Responsiveness Using Surrogate Evaluation Methods

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01438944
• Other study ID #: 2011039
• Status: Completed
• Phase: Phase 1
• First received: September 20, 2011
• Last updated: April 7, 2017
• Start date: July 2011
• Est. completion date: September 2015

Study information

• Verified date: April 2017
• Source: The Queen Elizabeth Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Evaluation to determine if auto-induction can be used as a surrogate measure of nicotine receptor up-regulation through an observational study using nicotine replacement therapy for two weeks and no intervention for two weeks.

Description:

Studies have shown that prolonged exposure to nicotine reinforces addiction. The act of smoking delivers nicotine through lungs into the blood stream. As a result, during smoking nicotine levels peak and then when smoking stops levels progressively diminish to a base (trough) level. At the peak level a smoker feels rewarded, but at the trough level a smoker starts to experience negative withdrawal affects and a desire to smoke. Nicotine Gum and Inhalers mimic this smoking behaviour maintaining a peak and trough regime, but nicotine patches do not. Instead, nicotine patches deliver a constant base dose considered to be either above that of the smokers trough level or at a level where negative withdrawal effects are reduced.

The question arises as to if nicotine levels delivered by a patch are constant and potentially above that of the baseline smokers level, does this reinforce the addiction and therefore contribute to the high long term relapse rate? To answer this question the investigators will be looking at metabolites which the body uses to breakdown nicotine and several other enzymes. These metabolites respond to the levels of nicotine in the blood stream by increasing or decreasing over time. By testing blood flow, blood and urine the investigators are able to gain an insight into how the body is dealing with a constant stable dose of nicotine rather than a peak and trough dose. In combination with the questionnaires the investigators will be able to determine the level of affect.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 52
• Est. completion date: September 2015
• Est. primary completion date: July 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Smokers who currently smoke at least 10 cigarettes per day

• Aged between 18 and 75

• Informed consent

• Willingness to attempt to quit smoking for the period specified, initially with a transdermal patch for 14 days and then without any smoking cessation aids for a further 14 days.

Exclusion Criteria:

• Use of bupropion, champix or nicotine containing products other than cigarettes in the last 2 months

• previous reactions to NRT

• Pregnancy / Breast Feeding

• Uncontrolled hypertension

• Unstable angina

• Heart attack or stroke within the previous 6 months

• Severe Obesity as indicated by Body Mass Index (BMI) =35 (potential for slow release of nicotine from tissues)

• acute psychiatric illness, past history psychosis, suicidal ideation or current diminished capacity.

• Current treatment or recent diagnosis of cancer

• Current use of Phenobarbital or other anticonvulsant drugs (induction of metabolism of nicotine to cotinine)

• Renal failure (creatinine clearance<30ml/min - reduces metabolic clearance of cotinine and nicotine)

Related Conditions & MeSH terms

• Addiction
• Behavior, Addictive
• Smoking

Intervention

Drug:
• Nicabate 21mg transdermal NRT
Nicabate 21mg Transdermal NRT Patch applied daily for 14 days Testing at Baseline, Day 4, Day 14 and 14 days post.

Locations

Country	Name	City	State
Australia	Kristin Carson	Adelaide	South Australia

Sponsors (6)

Lead Sponsor	Collaborator
The Queen Elizabeth Hospital	Basil Hetzel Institute for Translational Research, Clinical Practice Unit, Therapeutics Research Centre, University of Adelaide, University of South Australia

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline Nicotine, cotinine, Leptin and orexin Metabolite ratios	Baseline Prior to Transdermal NRT patch application Day 4 NRT Patch Application Day 14 Last Day NRT Patch Application Day 28 14 Days post NRT patch removal.	Baseline, Day 4, Day 14 and Day 28
Secondary	Change from baseline Patient Instruments: Fagerstrom Test for Nicotine Dependence (FTND), Wisconsin Smoking Withdrawal Scale (WSWS), Michigan Nicotine Reinforcement Questionnaire (MNRQ), Smoker Diary	Comparative evaluation patient instruments with ratios of metabolite induction	Baseline, Day 14 and Day 28